Please use this identifier to cite or link to this item: https://doi.org/10.1111/cts.12678
Title: First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug
Authors: Teneggi, V
Novotny-Diermayr, V
Lee, LH
Yasin, M
Yeo, P
Ethirajulu, K
Gan, SBH
Blanchard, SE
Nellore, R
Umrani, DN
Gomeni, R
Teck, DLW 
Li, G
Lu, QS
Cao, Y
Matter, A 
Issue Date: 1-Jan-2020
Publisher: Wiley
Citation: Teneggi, V, Novotny-Diermayr, V, Lee, LH, Yasin, M, Yeo, P, Ethirajulu, K, Gan, SBH, Blanchard, SE, Nellore, R, Umrani, DN, Gomeni, R, Teck, DLW, Li, G, Lu, QS, Cao, Y, Matter, A (2020-01-01). First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug. Clinical and Translational Science 13 (1) : 57-66. ScholarBank@NUS Repository. https://doi.org/10.1111/cts.12678
Abstract: © 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have emerged as modalities with an increase in scope and complexity of early clinical studies and first-in-human (FIH) studies in particular. However, limited work has been done to explore the impact of these two modalities, alone or in combination, on the scientific value and on the implementation of such articulated studies. We conducted an FIH study in HVs with an oncology targeted drug, an Mnk 1/2 small molecule inhibitor. In this article, we describe results, advantages, and limitations of an integrated clinical protocol with an oncology drug. We further discuss and indicate points to consider when designing and conducting similar scientifically and operationally demanding FIH studies.
Source Title: Clinical and Translational Science
URI: https://scholarbank.nus.edu.sg/handle/10635/187360
ISSN: 17528054
17528062
DOI: 10.1111/cts.12678
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 12 Kinase Inhibitor Oncology Drug.pdf424.99 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.